Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

Tonkin, A., Aylward, P., Colquhoun, D., Glasziou, P., Harris, P., MacMahon, S., Magnus, P., Newel, D., Nestel, P., Sharpe, N., Hunt, D., Shaw, J., Simes, R. J., Thompson, P., Thomson, A., West, M., White, H., Simes, S., Hague, W., Caleo, S., Hall, J., Martin, A., Mulray, S., Barter, P., Beilin, L., Collins, R., McNeil, J., Meier, P., Willimott, H., Smithers, D., Wallace, P., Sullivan, D. and Keech, A. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339 19: 1349-1357. doi:10.1056/NEJM199811053391902

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ247997_OA.pdf application/pdf 136.29KB 0

Author Tonkin, A.
Aylward, P.
Colquhoun, D.
Glasziou, P.
Harris, P.
MacMahon, S.
Magnus, P.
Newel, D.
Nestel, P.
Sharpe, N.
Hunt, D.
Shaw, J.
Simes, R. J.
Thompson, P.
Thomson, A.
West, M.
White, H.
Simes, S.
Hague, W.
Caleo, S.
Hall, J.
Martin, A.
Mulray, S.
Barter, P.
Beilin, L.
Collins, R.
McNeil, J.
Meier, P.
Willimott, H.
Smithers, D.
Wallace, P.
Sullivan, D.
Keech, A.
Title Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
Journal name New England Journal of Medicine   Check publisher's open access policy
ISSN 0028-4793
1533-4406
Publication date 1998-11-05
Year available 1998
Sub-type Article (original research)
DOI 10.1056/NEJM199811053391902
Open Access Status File (Publisher version)
Volume 339
Issue 19
Start page 1349
End page 1357
Total pages 9
Place of publication Waltham, MA, United States
Publisher Massachusetts Medical Society
Language eng
Abstract Background In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain.
Formatted abstract
Background: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain.

Methods: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease.

Results: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P< 0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin.

Conclusions: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Keyword Medicine, General & Internal
General & Internal Medicine
MEDICINE, GENERAL & INTERNAL
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3694 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4885 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 09 Sep 2011, 10:10:38 EST by System User on behalf of Learning and Research Services (UQ Library)